ID: ALA523672

Max Phase: Preclinical

Molecular Formula: C11H10NNaO4S

Molecular Weight: 253.28

Molecule Type: Small molecule

Representations

Synonyms (1): Deferitrin
Synonyms from Alternative Forms(1):

Canonical SMILES:  C[C@]1(C(=O)[O-])CSC(c2ccc(O)cc2O)=N1.[Na+]

Standard InChI:  InChI=1S/C11H11NO4S.Na/c1-11(10(15)16)5-17-9(12-11)7-3-2-6(13)4-8(7)14;/h2-4,13-14H,5H2,1H3,(H,15,16);/q;+1/p-1/t11-;/m1./s1

Standard InChI Key:  BCQHDKYWMJHLKR-RFVHGSKJSA-M

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 253.28

Molecular Weight (Monoisotopic): 253.0409

AlogP: 1.43

#Rotatable Bonds: 2

Polar Surface Area: 90.12

Molecular Species: ACID

HBA: 5

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.17

CX Basic pKa: 0.49

CX LogP: 2.50

CX LogD: -0.96

Aromatic Rings: 1

Heavy Atoms: 17

QED Weighted: 0.74

Np Likeness Score: 0.92

References

1. Bergeron RJ, Wiegand J, Bharti N, Singh S, Rocca JR..  (2007)  Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.,  50  (14): [PMID:17564424] [10.1021/jm070214s]

2. Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S..  (2008)  Desferrithiocin analogues and nephrotoxicity.,  51  (19): [PMID:18788724] [10.1021/jm8003398]

3. Bergeron RJ, Bharti N, Wiegand J, McManis JS, Singh S, Abboud KA..  (2010)  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.,  53  (7): [PMID:20232803] [10.1021/jm9018146]

4. Bergeron RJ, Wiegand J, Bharti N, McManis JS..  (2012)  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.,  55  (16): [PMID:22889170] [10.1021/jm300509y]

Source

Source(1):

• Scientific Literature